BioSpace News Archive

Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the company plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge, Massachusetts. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street

Leveraging its rich history of providing surgeons and their patients dynamic visualization experiences in the clinic and throughout the treatment continuum, Surgical Theater is proud that the Precision VR® platform is being featured at the Transcatheter Valve Therapies (TVT) Structural Heart Summit’s Late-Breaking Science Sessions in Chicago, IL.

India Globalization Capital, Inc. announces that its subsidiary Holi Hemp’s application has been approved and that it has executed agreements with operators to grow and harvest industrial hemp under the terms and conditions of the Industrial Hemp Program developed by the Arizona Department of Agriculture.

Cortellucci family makes historic $40-million donation to new Mackenzie Vaughan Hospital

In today’s world, the most popular technology is portable and usable on the go. Every year, while electronic products get smaller and smaller, it makes sense for consumers to move towards wearable technology.

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, follows the Company’s recent announcements on SRA737 with an update on other developments within its active preclinical portfolio.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ra Medical Systems, Inc. pursuant and/or traceable to the registration statement and prospectus issued in connection with Ra Medical’s September 2018 initial public offering.

The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.

Amgen and Allergan plc announced that the U.S. Food and Drug Administration has approved KANJINTI™ for all approved indications of the reference product, Herceptin®: for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.